Announced partnership with ProGen on development of RT-114, an oral GLP-1/GLP-2 dual agonist for the treatment of obesity -
- Phase 1 study for RT-114 expected to initiate in 2025 -
- Completed equity offering with gross proceeds of approximately $10.0 million -
- Presented clinical and preclinical data on oral delivery of an ustekinumab biosimilar via the RaniPill® Capsule at Digestive Disease Week 2024 -
https://finance.yahoo.com/news/rani-therapeutics-reports-second-quarter-200500551.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.